Menü Kapat

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience

Original Article

Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience

Receiving Date: 22 November 2021

Accept Date: 30 December 2021

Available Online: 20.03.2022

doi: 10.5455/medscience.2021.11.380

Med-Science. 2022; 11(2): 757-61

Conflict of Interests: The authors declare that they have no competing interests.
Financial Disclosure: All authors declare no financial support.
Ethical Approval: This study was approved by Fırat University Non-invasive Clinical Research Ethics Committee (date: 22.04.2021, approval number: 2021/06-09) and conducted in accordance with the Helsinki Declaration.

Table 1. Patients’ demographic and clinical features at the time of lenalidomide therapy.

 2,547 total views,  10 views today

Merter M, Uysal A.Lenalidomide treatment in relapsed/refractory B-cell lymphomas: A single center real-life experience. Med Science. 2022;11(2):757-61.

⇓ PlumX Meter

Corresponding Author: Mustafa Merter, Fırat University Faculty of Medicine, Department of Hematology, Elazıg, Turkey
E-mail: dr.mustafamerter@gmail.com